{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:56:01Z","timestamp":1791510961191,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":942,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1093\/annonc\/mdw685","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T12:05:49Z","timestamp":1482149149000},"page":"836-842","source":"Crossref","is-referenced-by-count":147,"title":["Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)"],"prefix":"10.1016","volume":"28","author":[{"given":"M.","family":"Rummel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Brugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Capochiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Plenteda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw685_bb0010","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw685_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw685_bb0020","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw685_bb0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw685_bb0030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw685_bb0035","unstructured":"Mabthera SmPC, https:\/\/www.medicines.org.uk\/emc\/ (1 August 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdw685_bb0040","unstructured":"Rituxan PI, http:\/\/www.fda.gov\/ (1 August 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdw685_bb0045","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mdw685_bb0050","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw685_bb0055","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(13)70383-8","article-title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","volume":"14","author":"Pivot","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw685_bb0060","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/bjc.2013.371","article-title":"Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase","volume":"109","author":"Shpilberg","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdw685_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"Davies","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw685_bb0070","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","article-title":"Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study","volume":"32","author":"Salar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw685_bb0075","unstructured":"Roche; http:\/\/www.roche.com\/media\/store\/releases\/med-cor-2014-03-28.html (1 August 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdw685_bb0080","first-page":"S483","article-title":"Subcutaneous versus intravenous rituximab in combination with CHOP for previously untreated diffuse large B-cell lymphoma: efficacy and safety results from the phase IIIB MABEASE study","volume":"100","author":"Lugtenburg","year":"2015","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw685_bb0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1524-4733.2007.00310.x","article-title":"Psychometric validation of the cancer therapy satisfaction questionnaire","volume":"11","author":"Trask","year":"2008","journal-title":"Value Health"},{"key":"10.1093\/annonc\/mdw685_bb0090","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/PPA.S108489","article-title":"Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab","volume":"10","author":"Theodore-Oklota","year":"2016","journal-title":"PPA"},{"key":"10.1093\/annonc\/mdw685_bb0095","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw685_bb0100","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/annonc\/mdu364","article-title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","volume":"25","author":"Pivot","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw685_bb0105","first-page":"A383","article-title":"Patient preference with subcutaneous vs intravenous rituximab combined with CHOP for untreated diffuse large B-cell lymphoma: results from the phase IIIb MABEASE study","volume":"33","author":"Lugtenburg","year":"2015","journal-title":"Hematol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:16:48Z","timestamp":1624695408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0923753419320575"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw685","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]}}}